BACKGROUND AND OBJECTIVE:ABO blood types are determined by antigen modifications on glycoproteins and glycolipids and associated with altered plasma levels of inflammatory and endothelial injury markers implicated in AKI pathogenesis. We sought to determine the association of ABO blood types with AKI risk in critically ill patients with trauma or sepsis.DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:We conducted two prospective cohort studies at an urban, academic, level I trauma center and tertiary referral center; 497 patients with trauma admitted to the surgical intensive care unit between 2005 and 2010 with an injury severity score >15 and 759 patients with severe sepsis admitted to the medical intensive care unit between 2008 and 2013 were followed for 6 days for the development of incident AKI. AKI was defined by Acute Kidney Injury Network creatinine and dialysis criteria.RESULTS:Of 497 patients with trauma, 134 developed AKI (27%). In multivariable analysis, blood type A was associated with higher AKI risk relative to type O among patients of European descent (n=229; adjusted risk, 0.28 versus 0.14; risk difference, 0.14; 95% confidence interval, 0.03 to 0.24; P=0.02). Of 759 patients with sepsis, AKI developed in 326 (43%). Blood type A again conferred higher AKI risk relative to type O among patients of European descent (n=437; adjusted risk, 0.53 versus 0.40; risk difference, 0.14; 95% confidence interval, 0.04 to 0.23; P=0.01). Findings were similar when analysis was restricted to those patients who did not develop acute respiratory distress syndrome or were not transfused. We did not detect a significant association between blood type and AKI risk among individuals of African descent in either cohort.CONCLUSIONS:Blood type A is independently associated with AKI risk in critically ill patients with trauma or severe sepsis of European descent, suggesting a role for ABO glycans in AKI susceptibility.

biomarkers of early renal impairment have been introduced. Two recent studies suggest early prognostic capabilities of the urinary test “nephrocheck” (NC). NC (Astute Medical, San Diego, CA, USA) is a bedside test providing the product of urinary concentrations of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinases-2 ([TIMP-2]*[IGFBP7]). Aim of the study: to compare the prediction of ICU-morality and requirement of renal replacement therapy (RRT) by NC to standard markers of renal function, APACHE-II-score and SOFA-score. Methods: After ICU-admission serum creatinine (0h; 24h; 48h), BUN (0h), cystatin C (0h) as well as NC ([TIMP-2]*[IGFBP7]) within 12h (NC-1) and within 36h (NC-2) were measured in 63 patients (26 female, 37 male). Furthermore, APACHE-II and SOFA-score were determined on the day of admission. Results:Results: n=63; age 61 ± 18 years; APACHE-II 18 ± 8; SOFA 6.8 ± 4. ICU-mortality was 8 of 63 patients (12.7%). Among all renal parameters determined within the first 36h only NC-2 significantly predicted ICU-mortality (AUC 0.767; p=0.023). By contrast, admission values of serum creatinine (AUC 0.539; p=0.743), BUN (0.597; p=0.408) and cystatin C (0.629; p=0.274), creatinine after 24h and 48h as well as NC-1 (0.616; p=0.325) did not predict ICU-mortality. Non-survivors had significant higher NC-2 values compared to survivors (17.2 ± 42.0 vs. 2.3 ± 5.3; p=0.034). A cut-off of 1.36 for NC-2 provided a sensitivity of 87% and a specificity of 72% for ICU-mortality. ROC-AUC regarding ICU-mortality was slightly higher for NC-2 (0.767) compared to the APACHE-II-score (0.753; p=0.0.31) and slightly smaller compared to the SOFA-score (0.787; p=0.015). The largest ROC-AUC was provided by a model including NC-2 and SOFA (0.797). Requirement of RRT was predicted NC-1 (0.758; p=0.008) and NC-2 (0.759; p=0.008). Conclusions: Nephrocheck (urinary concentrations of [TIMP-2]*[IGFBP7]) is an early predictor of ICU-mortality and requirement of RRT.